Supernus Pharmaceuticals (SUPN) EBT Margin (2011 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly EBT Margin of 26.32% for Q2 2026, down 3639.0% year-over-year from 0.74% in Q2 2025, and down 2808.98% on a QoQ basis from 0.9% in Q4 2025.
Supernus Pharmaceuticals (SUPN) EBT Margin (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported EBT Margin for 16 years, with the latest figure at 26.32% in Q2 2026.
- EBT Margin for Q2 2026 came in at 26.32%, down 3639.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 12.79% (down 2515.0% YoY), and the FY2025 annual result was 6.82%, down 2161.0% from the prior year.
- EBT Margin eased to 26.32% in Q2 2026, from 0.9% in the prior quarter.
- Over five years, EBT Margin peaked at 25.58% in Q3 2024 and troughed at 30.17% in Q3 2025.
- A 5-year average of 2.51% and a median of 5.86% in 2023 frame the typical range for EBT Margin.
- The widest annual swing landed in 2024, when EBT Margin surged 2826 bps; it then tumbled 5575 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 21.0% in 2022, then slumped by 97 bps to 0.6% in 2023, then soared by 2414 bps to 15.15% in 2024, then tumbled by 106 bps to 0.9% in 2025, then tumbled by 2809 bps to 26.32% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 26.32% in Q2 2026, 0.9% in Q4 2025, and 30.17% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | -26.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.32% |
| Dec 31, 2025 | -0.90% |
| Sep 30, 2025 | -30.17% |
| Jun 30, 2025 | 10.07% |
| Mar 31, 2025 | -3.89% |
| Dec 31, 2024 | 15.15% |
| Sep 30, 2024 | 25.58% |
| Jun 30, 2024 | 15.63% |
| Mar 31, 2024 | 0.17% |
| Dec 31, 2023 | 0.60% |
| Sep 30, 2023 | 6.43% |
| Jun 30, 2023 | -12.63% |
| Mar 31, 2023 | 5.86% |
| Dec 31, 2022 | 21.00% |
| Sep 30, 2022 | -0.25% |
| Jun 30, 2022 | 6.66% |
| Mar 31, 2022 | 9.65% |
| Dec 31, 2021 | 1.29% |
| Sep 30, 2021 | 19.51% |
| Jun 30, 2021 | 22.10% |